Comparison the effects and side effects of Covid-19 vaccination in patients with inflammatory bowel disease (IBD); A systematic scoping review

Tabesh, Elham; Soheilipour, Maryam; Rezaeisadrabadi, Mohammad; Zare‐Farashbandi, Elahe; Mousavi‐Roknabadi, Razieh Sadat

doi:10.21203/rs.3.rs-1812856/v1

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While most intestinal infections are temporary, 5 -30% of patients develop new, post-infectious GI symptoms even after the initial pathogen has been cleared. The advent of COVID-19, frequently associated with GI manifestations like diarrhea, abdominal pain, and nausea or vomiting (5)(6)(7)(8), has spurred research interest in the development of post-infectious GI symptoms. Similar to other infections that precipitate acute GI symptoms, COVID-19 can result in lasting conditions such as post-infectious IBS and post-viral gastroparesis (9).…”

Section: Introductionmentioning

confidence: 99%

Frequency and Risk Factors for Post-COVID-19 Functional Gastrointestinal Disorders After One Year

Soheilipour,

Ahoon,

Ghaderi

et al. 2024

Shiraz E-Med J

View full text Add to dashboard Cite

Objectives: In light of the global COVID-19 pandemic and the subsequent emergence of functional gastrointestinal disorders (FGIDs) post-recovery, this study aimed to evaluate the frequency and risk factors associated with FGIDs one year after recovering from COVID-19. Methods: This cross-sectional study included a total of 357 patients who had recovered from COVID-19 for a year and were seen at Al-Zahra Hospital in 2021. Participants were chosen through simple random sampling. The ROME questionnaire, alongside patients' clinical histories regarding irritable bowel syndrome (IBS) and its variants, functional dyspepsia (FD), and other GI symptoms, was utilized for data collection. Results: Findings indicated that one year post-COVID-19, the prevalence rates of IBS, GI symptoms, and FD stood at 15.4%, 44.9%, and 9.5%, respectively. It was observed that women had a higher propensity than men to develop these FGIDs (P-value = 0.044). Anxiety was linked to a 1.910-fold increase in IBS risk (P-value = 0.039), a 2.225-fold surge in GI symptoms (P-value < 0.001), and a 1.110-fold rise in FD risk (P-value = 0.042). Moreover, depression was associated with a 1.772-fold and 3.753-fold elevated risk of developing IBS (P-value = 0.040) and FD (P-value < 0.001), respectively. Conclusions: The findings suggest that FGIDs such as IBS, FD, and other GI symptoms are significant long-term sequelae of COVID-19 infection. Anxiety and depression appear to be key risk factors for these conditions, with a more pronounced impact observed in women than in men.

show abstract